Skip to main content
Premium Trial:

Request an Annual Quote

Agendia's MammaPrint Available from Two US Centers

NEW YORK (GenomeWeb News) - Agendia has begun the US roll-out of its MammaPrint breast cancer test, which is aimed at helping physicians predict the likelihood of cancer metastasis, through agreements with two university reference centers.
Agendia COO Jan Groen said in a statement that the first US centers offering the test are the University of California at San Francisco’s Medical Center at Mount Zion and the Baylor College of Medicine’s Dan L. Duncan Cancer Center.
In addition to the two reference centers, the company is offering the test to physicians through a mail-in system, company CEO Bernhard Sixt told GenomeWeb Daily News sister publication BioArray News.
Sixt said that doctors can submerge a tumor sample into a vial provided by RNARetain and send it via FedEx to Agendia's labs in Amsterdam. RNARetain is an RNA-stabilizing solution that allows tumor biopsies to be shipped without the need for freezing or cooling. Doctors will receive their results within seven to ten days after the biopsy is taken, he added.
The MammaPrint was the first in vitro diagnostic multivariate assay device approved by the US Food and Drug Administration since the agency released a draft guidance that described such products in 2006.

The Scan

Harvard Team Report One-Time Base Editing Treatment for Motor Neuron Disease in Mice

A base-editing approach restored SMN levels and improved motor function in a mouse model of spinal muscular atrophy, a new Science paper reports.

International Team Examines History of North American Horses

Genetic and other analyses presented in Science find that horses spread to the northern Rockies and Great Plains by the first half of the 17th century.

New Study Examines Genetic Dominance Within UK Biobank

Researchers analyze instances of genetic dominance within UK Biobank data, as they report in Science.

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.